Q-omics provides the consensus-scored EFCAB1 profile across patient tissues and cancer cell-line models. EFCAB1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, EFCAB1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, EFCAB1 RNA expression shows 14,699 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, KIRC, and TGCT as cancer lineages where EFCAB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EFCAB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EFCAB1 survival associations across molecular data types. EFCAB1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EFCAB1 RNA expression–survival associations across cancer types. High EFCAB1 expression shows unfavorable associations in KICH, BLCA and ACC, but favorable associations in BRCA, UVM and UCEC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for EFCAB1 RNA expression.
This table summarizes EFCAB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for EFCAB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EFCAB1 shows lower tumor expression in KIRC, LUAD, KICH, COAD, LUSC and UCEC. The KIRC box plot shows higher EFCAB1 RNA expression in normal versus tumor tissue (log2 FC = −0.125, t-test p < 0.001).
This table shows molecular features associated with EFCAB1 in patient tissues and cancer cell lines. In patient samples, EFCAB1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, EFCAB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
